We are live on ! Find out more
ENZ

Enzo Biochem, Inc.
ENZ

Delisted

ENZ was delisted on the 17th of April, 2025.

Back to rankings

46 hedge funds and large institutions have $22.8M invested in Enzo Biochem, Inc. in 2023 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

233% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 3

18% more funds holding

Funds holding: 39 → 46 (+7)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

1% less capital invested

Capital invested by funds: $23.1M → $22.8M (-$312K)

11% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 9

Holders
46
Holders Change
+7
Holders Change %
+17.95%
% of All Funds
0.67%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
10
Increased
8
Reduced
9
Closed
3
Calls
$62K
Puts
–
Net Calls
+$62K
Net Calls Change
-$69K

Top Buyers

Rank Fund Capital Flow
1
AFM
Anson Funds Management
Texas
+$306K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$196K
3
FIA
FNY Investment Advisers
New York
+$101K
4
Morgan Stanley
Morgan Stanley
New York
+$101K
5
WIM
Wittenberg Investment Management
Massachusetts
+$90.2K

Top Sellers

Rank Fund Capital Flow
1
TCM
Tang Capital Management
California
-$663K
2
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$150K
3
Renaissance Technologies
Renaissance Technologies
New York
-$102K
4
SC
Shay Capital
New York
-$87.5K
5
SMA
Sage Mountain Advisors
Georgia
-$12.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
HFA
1
Harbert Fund Advisors
Alabama
$7.19M – – –
Renaissance Technologies
2
Renaissance Technologies
New York
$3.45M -$102K -76,869 -3%
Vanguard Group
3
Vanguard Group
Pennsylvania
$2.61M +$196K +147,538 +9%
TCM
4
Tang Capital Management
California
$2.36M -$663K -500,000 -23%
PCM
5
Potomac Capital Management
New York
$2.06M +$35.5K +26,742 +2%
BlackRock
6
BlackRock
New York
$1.33M -$2.29K -1,727 -0.2%
Dimensional Fund Advisors
7
Dimensional Fund Advisors
Texas
$1.01M -$150K -113,404 -13%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$470K – – –
RC
9
RBF Capital
California
$348K – – –
AFM
10
Anson Funds Management
Texas
$321K +$306K +231,094 New
BCM
11
Bridgeway Capital Management
Texas
$316K – – –
State Street
12
State Street
Massachusetts
$232K – – –
Morgan Stanley
13
Morgan Stanley
New York
$211K +$101K +75,871 +100%
Northern Trust
14
Northern Trust
Illinois
$158K +$12.1K +9,145 +9%
FIA
15
FNY Investment Advisers
New York
$105K +$101K +75,911 New
Assenagon Asset Management
16
Assenagon Asset Management
Luxembourg
$101K -$11.6K -8,781 -11%
WIM
17
Wittenberg Investment Management
Massachusetts
$94.5K +$90.2K +68,003 New
Lazard Asset Management
18
Lazard Asset Management
New York
$70K – – –
T. Rowe Price Associates
19
T. Rowe Price Associates
Maryland
$63K – – –
Bank of New York Mellon
20
Bank of New York Mellon
New York
$36.4K – – –
Millennium Management
21
Millennium Management
New York
$35.2K +$33.6K +25,309 New
KCM
22
Kempner Capital Management
Texas
$35K – – –
SCA
23
Snowden Capital Advisors
New York
$28.4K -$1.4K -1,054 -5%
TPA
24
Trivium Point Advisory
Connecticut
$27.1K – – –
AWM
25
AE Wealth Management
Kansas
$26K – – –
1
2

ENZ Hedge Fund Activity: Q4 2023 in Review

46 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Enzo Biochem, Inc. (ENZ) for Q4 2023, worth a combined $22.8M — down 1.3% from $23.1M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new ENZ positions and 3 closed out — a net gain of 7 holders — while 8 added to existing stakes and 9 trimmed.

The largest buyer was Anson Funds Management, opening a new position worth an estimated $306K. The largest seller was Tang Capital Management, cutting an estimated $663K.

  • 46 institutional investors held Enzo Biochem, Inc. (ENZ) as of Q4 2023, up from 39 in Q3 2023.
  • Funds reported $22.8M of Enzo Biochem, Inc. stock for Q4 2023, down 1.3% quarter-over-quarter.
  • 10 funds opened new Enzo Biochem, Inc. positions in Q4 2023 and 3 closed out, a net change of +7 holders.
  • The largest Enzo Biochem, Inc. buyer in Q4 2023 was Anson Funds Management, an estimated $306K added.
  • The largest Enzo Biochem, Inc. seller in Q4 2023 was Tang Capital Management, an estimated $663K sold.

Based on aggregated 13F filings for Q4 2023.